The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Capital Markets Day will attract institutional investors with the real bucks. Watch this share price begin to motor.
From today's rns:
Capital Markets Day
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it is hosting its Capital Markets Day today at the offices of Deutsche Numis, London at 3pm GMT.
The Company will provide greater detail on the commercial and clinical progress of its products and will feature presentations from a number of NHS clinicians who are using Creo's products in practice. The agenda of the event will include presentations from:
· Dr Sal Khalid, Consultant Gastroenterologist and Clinical Lead for Endoscopy at The Pennine Acute Hospitals NHS Trust: "How Speedboat Submucosal Dissection is helping Oldham tackle bowel cancer"
· Dr Adolfo Parra-Blanco, Consultant Gastroenterologist, Hepatologist, Nottingham NHS Treatment Centre: "Why Speedboat is so effective at reducing patient complications in the Upper GI tract"
· Mr Tom Routledge, Consultant Thoracic Surgeon, Guy's and St. Thomas' NHS Foundation Trust: "Creo Medical - A surgeon's perspective"
The event is open to institutional investors, sell-side analysts and media only. To request a place at the event, please contact Walbrook PR on +44 (0)20 7933 8780 or creo@walbrookpr.com.
No new material information will be disclosed during the event.
Perhaps not a sexy company, however the FDAs acceptance of CREOs leading product is a game changer. The sales will soon start rolling in and the SP here will rise accordingly.
03-Nov-23 16:31:35 32.83 30,500 Buy* 32.50 33.00 10.01k O
03-Nov-23 16:00:45 32.83 33,500 Buy* 32.50 33.00 11.00k
Https://www.investormeetcompany.com/investor/meeting/investor-presentation-421
Well worth a listen.
Clever investors should get in now, before the upcoming good news.
Does anyone know if CREO has a capital markets day on Nov 7th? I thought there was but now can't find any info on it
Shiver me timbers, Speedboats away! Full throttle, if you'll pardon the awkward connotations. So we finally have a MATURE product in the marketplace. It's sink or swim time!
For LTHs this probably looks like a no-brainer for an acceleration in revenue, but the market is wary
Looks like another big RNS might be on the way.
Finishes the day…. exactly where it started! What exactly does this company need to do?
Not necessarily. There plenty of small caps that rise on good news. All we require here , is for investors to realise how Game Changing the RNS was.
This is what happens in a small cap bear market
I agree Grange. I think the markets will wake up to this , this afternoon. We also have offices in the States, so should be a good reaction when their markets open. Along with the European approval coming much sooner than expected, this is Monumento's news.
Very poor sp reaction to such good news
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, is pleased to announce that it has received 510(k) clearance from the US Food & Drug Administration ("FDA") for its Speedboat® UltraSlim device.
Fantastic news for the SP.
Another positive aspect of the RNS is the fact that they have managed to 'scale the technology down to a size which is as small as it ever needs to be'. This suggests that any future development costs will be substantially 'scaled down' too. (: It also suggests they have made technological breakthroughs which can potentially be applied across the product range.
The acceleration of regulatory timescales just adds to the feeling that the company is genuinely on a rapid upwards trajectory, not just issuing hopeful words like far too many small businesses.
Agreed, feels really significant. Be interested to see whether this leads to a revision on when CREO expects to achieve breakeven point.
Market response doesn't seem to agree with my views on this bit of news, but it's a bit of a sh*tshow out there at the moment so trying not to take it as personal to CREO. I guess until the approvals actually come from Europe and the US, it's a nice to know, but not 100% , so when we actually get those approvals that's when it will get priced in to the share price. At least I hope so, watching this bob along at 32p-35P is frustrating at times
Sorry error on my part. 2025 should have read 2024. Typo
"With this news, the accelerated timeframes will now see Creo, clinicians and patients reaping the benefits of widespread commercialisation of Speedboat UltraSlim in both Europe and the US in 2024."
Early 2024 has been stated elsewhere, I feel this news is quite significant and (if I read it right) shows the eagerness of the regulatory bodies to support CREO in getting their impressive tech into use for a wider range of surgical applications. Seems great to me !
Early launch of the UltraSlim in the EU has to be good news. 2025 is not so far away now. Lets hope the cost of the launch, training and familiarisation is not too onerous. Still the launch should eventually translate to sales, income and eventually profit. Hopefully!!. Fairly muted response share price wise and some of the larger 'unknown trades' could well be sells but that's a guess to be honest.
There was an incident on the London stock exchange on the 19th, trading in lots of stocks were halted, resumed on the 20th.
Trading halted on T212 before close. Hmmm
ShareSoc is holding its first hybrid event in London on 19th Oct! Hear from Creo Medical Group (CREO) and other healthcare companies like Tristel Plc (TSTL), Inspiration Healthcare Group (IHC), Abingdon Health (ABDX) and GENincode (GENI). 📍🌐 Attend in-person or online. Register: https://bit.ly/3FbyXfe
Winit, having a read CMR must be a player, the fact they are a UK company helps and certainly they are getting real traction in Europe. Intuitive utterly dominates the US market. I suppose that if Creo were able to choose they would run with both rather than narrow their focus. It does puzzle me that we haven’t seen more progress. I have absolute faith in the Creo technology, maybe it’s the nature of the market and all the technical issues, it just takes an eternity for these relationships to develop given all the medical risks, lots of trials and testing I guess. Hopefully next time Creo report we will see an update on all of this.
With CMR surgical to consider also (another very large robotic based med device company) little Creo are interfacing with some similar? big boys.
It feels like an interesting situation. I expect/hope something significant will come from these relationships.
Can Intuitive and CMR be considered competitors ?